IF it's true what Richard said regarding CPI-818 specificity regarding its ability to differentiate between ITK and RLK (the difference being only amino acid between these two related kinases), then this molecule will have a huge potential in autoimmune diseases that originate from Th2 dysfunction. That alone is a mega blockbuster, $20bil+.
IF the skewing of lymphocytes toward Th1 (the killer cells that eliminate cancer cells and viral infection) is the mechanism of action of CPI-818, and we see similar objective response rate in solid tumors for patients with ALC > 900 or who have normal ALC of 100-4000, then this molecule will be used with every approved drugs in solid tumors. That alone is a mega blockbuster. Potential value there is unprecedented, off the chart. Corvus is planning to start a Phase 1 study with CPI-818 (I'm assuming at the optimal dose of 200mg twice daily) as early as this year, so we won't get that glimpse of initial clinical data until late next year at the earliest, if not mid 2025.
Recent CRVS News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2024 09:19:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 09:16:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:06:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:11:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:01:14 PM
- Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/06/2024 08:01:00 PM
- Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 • GlobeNewswire Inc. • 05/02/2024 08:02:00 PM
- Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering • GlobeNewswire Inc. • 05/02/2024 12:30:00 PM
- Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis • GlobeNewswire Inc. • 04/09/2024 08:01:00 PM
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/19/2024 08:02:00 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024 • GlobeNewswire Inc. • 03/13/2024 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:57:04 PM
- Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases • GlobeNewswire Inc. • 02/12/2024 01:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:27:12 PM
- Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma • GlobeNewswire Inc. • 02/08/2024 09:05:00 PM
- Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer • GlobeNewswire Inc. • 02/06/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:00:15 PM
- Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell • GlobeNewswire Inc. • 01/23/2024 10:00:00 PM
- Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial • GlobeNewswire Inc. • 12/09/2023 05:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:07:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:03:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:03:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:02:38 PM
- Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 09:01:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM